drugset / Trial / NCT00808418

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

NCT00808418 ↗

Phase 1 Completed 34 enrolled Synta Pharmaceuticals Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.

Timeline

Start
2008-11
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — —
Subject Elesclomol Small molecule — —

Indications